Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on molecular pathways that protect the cells.
* This article was originally published here
This Blog Is Powered By The Life Technology™ News And Advertising Network. Subscribe To This Blog Via Feedburner / Atom 1.0 / RSS 2.0.